This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Jansson, A Articles by Vrethem, M Search for Related Content PubMed PubMed Citation Articles by Jansson, A Articles by Vrethem, M Social Bookmarking                   What's this?

Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferon-b1a or glatiramer acetate compared with untreated patients

Clinical Research Centre and Department of Molecular and Clinical Medicine, Division of Clinical Immunology, Linköping University, S-581 85 Linköping, Sweden

J Ernerudh

Clinical Research Centre and Department of Molecular and Clinical Medicine, Division of Clinical Immunology, Linköping University, S-581 85 Linköping, Sweden

M Kvarnström

Clinical Research Centre and Department of Molecular and Clinical Medicine, Division of Clinical Immunology, Linköping University, S-581 85 Linköping, Sweden

C Ekerfelt

Clinical Research Centre and Department of Molecular and Clinical Medicine, Division of Clinical Immunology, Linköping University, S-581 85 Linköping, Sweden

M Vrethem

Department of Neuroscience and Locomotion, Division of Neurology and Neurophysiology, Faculty of Health Sciences, Linköping University, S-581 85 Linköping, Sweden, magnus.vrethem{at}lio.se

The mechanisms behind the beneficial effects of interferon-b1a (IFN-b1a) and glatiramer acetate (GA) in the treatment of multiple sclerosis (MS) are still uncertain. A ltered cytokine patterns have been suggested including inhibition of proinflammatory cytokines like interferon-g (IFN-g) and enhancement of anti-inflammato ry cytokines such as interleukin-4 (IL-4). Twenty-nine patients with MS (10 untreated, nine treated with IFN-b1a and 10 with GA) were investigated with elispot of peripheral blood mononuclear cells. Spontaneous and myelin induced (myelin basic protein (MBP), myelin oligodendro cyte glycoprotein (MO G)-14-39 and MO G 63-87) IFN-g, IL-4, IL-5 and IL-10 secretion was studied. We found a significant reduction of spontaneous IFN-g, IL-4 and IL-5, but no difference in IL-10 secreting cells in both groups of treated patients compared with the untreated patients. Myelin-specific responses showed a significant decrease of IFN-g and an increase of IL-5, but no change in IL-4 and IL-10 secreting cells in treated compared with untreated patients. Both treatment groups revealed similar cytokine secretion patterns except for a more pronounced decrease of both spontaneous and MO G 14-39 induced IL-4 secretion in the IFN-b1a treated group. Thus, immunological effects of IFN-b1a and G A were similar showing that disease promoting Th1 (IFN-g) cells were reduced while the potentially beneficial Th2 response (IL-4) was maintained.

Key Words: elispot • glatiramer acetate • interferon-ß • multiple sclerosis • myelin basic protein (MBP) • myelin oligodendrocyte glyco protein (MO G)

Multiple Sclerosis, Vol. 9, No. 5, 440-445 (2003)
DOI: 10.1191/1352458503ms951oa


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R.M. Valenzuela, K. Costello, M. Chen, A. Said, K.P. Johnson, and S. Dhib-Jalbut Clinical response to glatiramer acetate correlates with modulation of IFN-{gamma} and IL-4 expression in multiple sclerosis Multiple Sclerosis, July 1, 2007; 13(6): 754 - 762. [Abstract] [PDF]

				I. Teige, Y. Liu, and S. Issazadeh-Navikas IFN-beta Inhibits T Cell Activation Capacity of Central Nervous System APCs J. Immunol., September 15, 2006; 177(6): 3542 - 3553. [Abstract] [Full Text] [PDF]